5 days ago
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) Final Rule, effective October 1, 2025.
The AeroPace® System is an FDA-designated breakthrough device that uses periodic neurostimulation to exercise the diaphragm, helping mechanically ventilated patients to breathe independently faster. Clinical evidence shows that patients treated with the AeroPace System strengthened their diaphragm by 50%, reduced their risk of being on the ventilator for 30 days by 35%, and reduced ventilator time by 3 days when compared to standard of care.
